Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. - Wikidata - wikimedia - TriplyDB

Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts.

Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts.

http://www.wikidata.org/entity/Q42003359

about

Receptors for acylethanolamides-GPR55 and GPR119 The endocannabinoid system as an emerging target of pharmacotherapy Cardiovascular dysfunction in patients with liver cirrhosis Endocannabinoids, blood pressure and the human heart.In vivo effects of CB2 receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints.Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes Cannabidiol: an overview of some pharmacological aspects.Anandamide reduces intracellular Ca2+ concentration through suppression of Na+/Ca2+ exchanger current in rat cardiac myocytes.The complexities of the cardiovascular actions of cannabinoids Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries.Vascular effects of anandamide and N-acylvanillylamines in the human forearm and skin microcirculation.Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities.Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling.Pharmacological profiling of the hemodynamic effects of cannabinoid ligands: a combined in vitro and in vivo approach Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions Rare Variants Association Analysis in Large-Scale Sequencing Studies at the Single Locus Level Blood pressure regulation by endocannabinoids and their receptors Significance of cannabinoid CB1 receptors in improgan antinociception.Cardiac and vascular changes in cirrhosis: pathogenic mechanisms.Cardiovascular pharmacology of cannabinoids.Therapy insight: Cirrhotic cardiomyopathy.Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis.Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension.Endocannabinoids and the heart.Cardiovascular changes in cirrhosis: pathogenesis and clinical implications.Cirrhotic cardiomyopathy: a cardiologist's perspective.Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors.GPR55 and the vascular receptors for cannabinoids The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints.Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats.Feasibility of targeting ischaemia-related ventricular arrhythmias by mimicry of endogenous protection by endocannabinoids.Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism.Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta.Cannabinoids inhibit noradrenergic and purinergic sympathetic cotransmission in the rat isolated mesenteric arterial bed.Endocannabinoids protect the rat isolated heart against ischaemia.Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery.Endocannabinoids as mediators in the heart: a potential target for therapy of remodelling after myocardial infarction?Involvement of CB1-receptors and beta-adrenoceptors in the regional hemodynamic responses to lipopolysaccharide infusion in conscious rats.

P2860

Q24647538-8EEE4158-0495-4978-94BE-6613C774E877 Q24648473-C8A92ADE-2D28-4741-970E-873E867C60B8 Q27010592-1C0EC573-BC45-454E-B1DE-CC4312569BFF Q30368944-3D008E97-2BF7-48F7-A860-2947A0C1FA32 Q33304983-18A33884-9B2F-44B0-9DD4-9CC489B2E3D1 Q33929785-41957A3D-EEF8-4AEC-B204-302B53F7D343 Q34157378-C682FFF1-27A0-4279-BE5C-C2F2CA951DB9 Q34718132-41FB5909-B097-446E-A9D1-BEEE740FCEDD Q35047093-350CC65A-F0FB-4F69-AA43-97D189BA5D58 Q35047182-7EB7BE4A-490F-4416-9727-B3135B1FD823 Q35049157-0C123389-9D3F-4A13-A523-E619936774FA Q35228889-5A08F724-C7D7-4379-BE8C-D177E95BBB95 Q35684044-BB7BDF05-D231-44F8-A1F1-12DB5477173B Q35822367-6E71A609-01C4-4574-BE33-108F25AD9D0F Q36052772-8D74AAD3-2ABF-4431-8BE5-22D9824AEFDF Q36063830-DC7897FC-D263-4286-839E-0AFF12A30702 Q36135785-988833A2-CD4F-4069-A7C4-0AB93F2081E1 Q36343184-A5365FCD-E590-47A8-93ED-70BA8233C9C8 Q36415452-A8BFEAED-CF32-4664-9497-CEE6F26D8A46 Q36431860-800CE455-044A-4129-918A-8AAAC0254194 Q36495176-0C72F147-CB72-45C3-89A1-478BF0DF65E7 Q36891652-D37FAE84-73B1-4984-81F3-52931A7F5E84 Q37243665-84D55959-B572-4E47-8376-AAF24D0DD952 Q37373710-54554A94-CB14-4CDB-A384-6312D5D1D29F Q37412217-235E6EA1-CBBE-4E79-AA7A-96C855696BAD Q37771146-5056FBC1-EFDB-4B58-97F4-495395DCAE13 Q38268611-E61E519C-F949-411A-8FFF-EBF9E133EA89 Q41832173-0C100887-D5FA-4698-A007-EAD5B452FDA5 Q41833587-9DEE3AE2-74A8-41D1-BFD5-D3BA6006468F Q41854357-AE384FEC-CFEF-4807-9EC3-90E9D8926457 Q42186844-F45A79AE-D050-4193-B5F8-2F6307B88303 Q42200119-312F360C-8D31-4A1F-BF2E-11F60BB6DAF4 Q42572010-8B9706E5-EB09-414C-9CC1-77768FEA8A1D Q42844430-6C47AE2F-60D3-4695-972C-39C0BB9720E1 Q42940476-275B7EC6-BF55-4E6C-995F-66FC082B5B5B Q42940490-E77EA800-2391-4D6D-9418-501590AE04D5 Q43263345-EB2D3C94-D848-48C9-897A-2C28F1E65DF2 Q43263458-6AC7DD06-1617-42C0-816C-9894C88124E7 Q43263467-CC816F58-2FB1-4EE3-B2A3-8E28E01ED553 Q45190193-E3D8B7F4-F6B7-47D9-A174-F02A7501B5D8

P2860

Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts.

http://www.wikidata.org/entity/Q42003359

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Evidence of a novel site media ...... ponses in rat isolated hearts.

@en

Evidence of a novel site media ...... ponses in rat isolated hearts.

@nl

type

label

Evidence of a novel site media ...... ponses in rat isolated hearts.

@en

Evidence of a novel site media ...... ponses in rat isolated hearts.

@nl

prefLabel

Evidence of a novel site media ...... ponses in rat isolated hearts.

@en

Evidence of a novel site media ...... ponses in rat isolated hearts.

@nl

P1433

Q42003359-12C92FC3-4EF1-438F-AEC2-3D07039281F3

P1476

Q42003359-DBC21216-6F04-42A7-8E0D-07CFE9471365

P2093

Q42003359-47A1590C-A5E7-447B-A91C-3CA679C3F20E

Q42003359-A14BC7A4-CA39-4D7E-A161-FDA014F09739

P2860

Q42003359-00BF20C3-AD45-4143-86A6-AB1C8420195C

Q42003359-0CE9EDBA-5EB8-4C46-AD72-FFBA1D7EB0C4

Q42003359-0DBC5A40-B74B-4FEB-BC09-EDB544A48205

Q42003359-1184AAE5-0711-418F-B53B-8ACBF4C19097

Q42003359-1FE18EFD-BE2A-49FA-8D9A-27790269FEE6

Q42003359-2DA5BA86-FA87-48A4-BB1D-D7419861689C

Q42003359-320FFF4F-3F80-45B9-9EAA-06CB7A3FD9BF

Q42003359-33E01C36-96BC-427F-9C39-CE8AF713F335

Q42003359-3A30CDC2-234D-4F70-8BD6-F7F13852A3AE

Q42003359-47204524-BB79-49B8-8096-CBB30CC52D78

P304

Q42003359-A57A5884-9304-43B3-BF6D-B0472C1EF7C3

P31

Q42003359-95E3E2AD-AEA0-468C-954F-D1329565D8C6

P356

Q42003359-704B2D04-EFA9-4948-B345-13B64FC852AA

P407

Q42003359-895F02BC-8B6F-48C2-869C-5FF0130DE09E

P433

Q42003359-414E44E2-B8C5-402E-B076-6A7BE632281A

P478

Q42003359-55BBC315-7BCC-41EE-807C-DF3FB7CB0532

P50

Q42003359-173ADA93-EDDA-4CB2-BD42-91D821E5F2A7

Q42003359-BA413054-0A21-4613-B50F-0A94626E2DF1

P577

Q42003359-E2357108-B56C-457E-AC8B-115CB77211F6

P5875

Q42003359-86259F3D-333F-4B85-B577-5E2D8ADAD80A

P698

Q42003359-BB8AB14B-63BA-485F-961B-DAAB57FF4F19

P921

Q42003359-4CF340C7-A40B-406B-9557-1EB22EE028A0

Q42003359-5540895F-A2D8-43E7-ACD1-52AF79040E73

P932

Q42003359-DB32E3DF-2B2B-42B7-A158-E55C1567F1CD

P356

P1433

British Journal of Pharmacology

P1476

Evidence of a novel site media ...... sponses in rat isolated hearts

@en

P2093

Stuart A Honan

http://www.w3.org/2001/XMLSchema#string

William R Ford

http://www.w3.org/2001/XMLSchema#string

P2860

Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors

Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist

2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain

Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors

Molecular characterization of a peripheral receptor for cannabinoids

The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)

A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus

Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide

P304

1191-1198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJP.0704565

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

135

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11486053

http://www.w3.org/2001/XMLSchema#string

P698

11877326

http://www.w3.org/2001/XMLSchema#string

P921

P932

1573229

http://www.w3.org/2001/XMLSchema#string